The GLP-1 mimetic Liraglutide reduced AD hallmarks such as amyloid plaque load, memory loss, synapse loss, impaired synaptic transmission (LTP), and the chronic inflammation response in the brain (McClean et al., 2011, 2015; McClean and Holscher, 2014a). This evidence concerns the gene GCG and Alzheimer disease.